Gravitas was founded to acquire and advance the development of GR-2397, a novel clinical-stage antifungal agent for the treatment of immunocompromised patients with serious fungal infections.

Gravitas acquired the rights to GR-2397 in 2021 and, after conducting value-adding R&D, sold it in 2023 to Basilea Pharmaceutica Ltd (SIX: BSLN), a leading antimicrobial pharmaceutical company.

 

 

August 2020

Gravitas’ Inception

 

December 2021

Gravitas Purchases GR-2397 for Treatment of Severe Fungal Infections

 

October 2023

Gravitas Announces Asset Sale of GR-2397 Antifungal to Basilea Pharmaceutica Ltd

 

December 2023

Gravitas Purposefully Dissolved / Dispersing Agent Assigned to Manage the Receipt and Distribution of Potential Future Milestone Payments